<DOC>
	<DOCNO>NCT02678338</DOCNO>
	<brief_summary>This phase I trial study side effect best dose anti-cluster differentiation ( CD ) 47 monoclonal antibody Hu5F9-G4 treating patient acute myeloid leukemia return period improvement ( relapse ) respond previous treatment ( refractory ) . Monoclonal antibody , anti-CD47 monoclonal antibody Hu5F9-G4 , block cancer growth different way target certain cell .</brief_summary>
	<brief_title>CAMELLIA : Anti-CD47 Antibody Therapy Relapsed/Refractory Acute Myeloid Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Key Pathologically confirm relapsed refractory ( primary refractory relapse refractory ) Acute Myeloid Leukemia ( AML ) ( define World Health Organization ( WHO ) criterion ) conventional therapy suitable patient within 3 week registration . Male female , Age ≥ 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance score 0‐1 Willing undergo blood transfusion deem clinically necessary . Adequate hematological , liver , kidney function Key Females : Pregnant breast‐feeding woman , woman childbearing potential unless effective method contraception use 3 month trial . Males : unless effective method contraception use 3 month trial . Any prior exposure Hu5F9‐G4 CD47 target agent . Treatment investigational agent within 28 day prior enrolment . Previous allogeneic stem cell transplant Evidence active CNS involvement leukaemia Clinical evidence know history cardiopulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>